|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00056693 |
Purpose
To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
| Condition | Intervention | Phase |
|
Neuroendocrine Tumors |
Drug: Sunitinib |
Phase II |
| MedlinePlus related topics: | Cancer |
| Drug Information available for: | Sunitinib Sunitinib malate |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor |
| Enrollment: | 107 |
| Study Start Date: | April 2003 |
| Study Completion Date: | September 2006 |
| Primary Completion Date: | September 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
| A: Experimental |
Drug: Sunitinib
Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
|
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Alabama | |||||
| Pfizer Investigational Site | |||||
| Birmingham, Alabama, United States, 35233 | |||||
| Pfizer Investigational Site | |||||
| Birmingham, Alabama, United States, 35294 | |||||
| United States, California | |||||
| Pfizer Investigational Site | |||||
| San Francisco, California, United States, 94115-1705 | |||||
| Pfizer Investigational Site | |||||
| Los Angeles, California, United States, 90033 | |||||
| Pfizer Investigational Site | |||||
| Los Angeles, California, United States, 90033-0800 | |||||
| United States, Illinois | |||||
| Pfizer Investigational Site | |||||
| Pinckneyville, Illinois, United States, 62274 | |||||
| United States, Massachusetts | |||||
| Pfizer Investigational Site | |||||
| Boston, Massachusetts, United States, 02114 | |||||
| Pfizer Investigational Site | |||||
| Boston, Massachusetts, United States, 02115 | |||||
| Pfizer Investigational Site | |||||
| Boston, Massachusetts, United States, 02215 | |||||
| United States, Missouri | |||||
| Pfizer Investigational Site | |||||
| St Louis, Missouri, United States, 63110 | |||||
| Pfizer Investigational Site | |||||
| St. Louis, Missouri, United States, 63110 | |||||
| United States, Pennsylvania | |||||
| Pfizer Investigational Site | |||||
| Philadelphia, Pennsylvania, United States, 19111 | |||||
| Pfizer |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
To obtain contact information for a study center near you, click here. 
  |
Link to ClinicalStudyResults.org Posting 
  |
| Responsible Party: | Pfizer Inc ( Director, Clinical Trial Disclosure Group ) |
| Study ID Numbers: | RTKC-0511-015 |
| First Received: | March 20, 2003 |
| Last Updated: | July 18, 2008 |
| ClinicalTrials.gov Identifier: | NCT00056693 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|